STOAF II portfolio company PERCEPIO ANNOUNCES SUCCESSFUL CLOSING OF A 22 MSEK (2.3 MUSD) SERIES A FUNDING ROUND
Percepio announces the successful closing of a 22 MSEK (2.3 MUSD) Series A funding round led by Fairpoint Capital AB. The investment is intended to scale up operations and accelerate the product development roadmap, with a focus on embedded software and Internet of Things (IoT).
Percepio is pioneering the area of visual trace diagnostics, which has a great potential for helping developers cope with runtime complexity. Percepio is uniquely positioned to provide visual trace diagnostics to a broad range of software organizations. The funding will allow the company to reach many new customers and help them build amazing products, on time and on budget.
STOAF III SciTech invests in sustainable water cleaning company Stockholm Water Technology
STOAF III SciTech, Almi Invest and SEA (Sustainable Energy Angels) are investing a total of SEK 10 million in Stockholm Water Technology, which offers smart, clean, and sustainable water purification solutions primarily for industrial use. The money will go towards market introduction and product development.
STOAF III SciTech invests in Aligned Bio
Aligned Bio, a single molecule detection company, announced an oversubscribed A round investment of 23 MSEK led by STOAF III SciTech and Fårö Capital. Previous investors Almi Invest and MIST Ventures continued their participation.
STOAF III SciTech invests in Stroke Alarm company Uman Sense
In an oversubscribed new share issue, the medtech company Uman Sense has raised SEK 6.3 million. Among the new co-owners are STOAF III SciTech, Gobia Enterprises, and Queen Invest. Uman Sense has developed and CE-marked the medical device Stroke Alarm, a medical device which is now being tested in a clinical trial on patients at a high risk for stroke.
STOAF III SciTech invests in Developeration’s innovative surgical device
STOAF III SciTech och Almi Invest each invests 1.9 MSEK in Developeration AB, who has developed an innovative surgical instrument for treatment of hemmorhoids. The emission of 4.4 MSEK will be used for further product development and clinical trials. Hemorrhoids affect about 25 percent of the population over the age of 50 in the Western world. There are currently several different ways to treat hemorrhoids, but they carry a high risk of recurrence or complications, are expensive, take a long time, require access to the operating theater, are painful, or a combination of these.
STOAF II portfolio company PERCEPIO ANNOUNCES SUCCESSFUL CLOSING OF A 22 MSEK (2.3 MUSD) SERIES A FUNDING ROUND
Percepio announces the successful closing of a 22 MSEK (2.3 MUSD) Series A funding round led by Fairpoint Capital AB. The investment is intended to scale up operations and accelerate the product development roadmap, with a focus on embedded software and Internet of Things (IoT).
STOAF II PORTFOLIO COMPANY ILYA PHARMA AWARDED €5.3M FROM EIC ACCELERATOR
STOAF II PORTFOLIO COMPANY ILYA PHARMA AWARDED €5.3M FROM EIC ACCELERATOR TO FAST TRACK PHASE II STUDY OF FIRST-IN-CLASS ILP100 ADVANCE THERAPY FOR WOUND TREATMENT IN PEOPLE WITH DIABETES Ilya Pharma, a clinical stage biopharma company developing novel chemokine gene therapies with its ILP-technology platform, today announced that it has secured a total of Euros 5.3 million in funding from the European Innovation Council (EIC) Accelerator program of blended financing.